We can’t show the full text here under this license. Use the link below to read it at the source.
Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
Glucagon-like peptide-1 drugs and their effects on insulin, glucagon, and stomach emptying in Japanese people with type 2 diabetes
AI simplified
Abstract
Eighteen subjects with type 2 diabetes showed significant reductions in HbA1c after 12 weeks of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs).
- Lixisenatide and liraglutide significantly reduced body weight, whereas dulaglutide did not.
- Postprandial glucose elevation was improved by all three GLP-1RAs.
- Postprandial insulin levels were suppressed by lixisenatide but enhanced by liraglutide.
- Lixisenatide suppressed postprandial glucagon levels, while liraglutide and dulaglutide had limited effects.
- Gastric emptying was significantly delayed by lixisenatide, with liraglutide and dulaglutide showing limited effects.
- GIP secretion was suppressed by both lixisenatide and liraglutide, while apolipoprotein B48 secretion was suppressed by all GLP-1RAs.
AI simplified
Key numbers
12 weeks
HbA1c Reduction
All GLP-1RAs improved HbA1c levels after 12 weeks.
2 of 3
Body Weight Reduction
Lixisenatide and liraglutide significantly reduced body weight, while dulaglutide did not.
18
Participants
Eighteen Japanese individuals with type 2 diabetes participated in the study.